ADMEDUS ANNOUNCES EXCLUSIVE SUPPLY AGREEMENT WITH 4C MEDICAL MINNEAPOLIS, MN – Admedus Limited (ASX:AHZ) today announced that it has entered into an exclusive supply agreement with 4C Medical Technologies, Inc. (4C Medical), a Minnesota-based developer of minimally invasive therapies for structural heart disease. Under the agreement, 4C Medical will add the latest innovation in cardiovascular tissue engineering from Admedus to their novel transcatheter mitral regurgitation treatment technology that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology. The novel design eliminates known issues of current transcatheter mitral valve replacement (TMVR) technologies which rely on placement and fixation in the native mitral annulus and left ventricle. Specifically, the functioning valve apparatus of the 4C implant will utilize tissue processed by Admedus’ clinically superior ADAPT® Tissue Engineering Process for the functioning leaflet component. This additional key technology optimizes function and durability.1 “We are looking forward to supplying our ADAPT tissue products for 4CMedical, which we are confident will give Admedus access to a significant new revenue stream ,said Admedus CEO Wayne Paterson. “4C Medical has already made significant progress on its development path in the very challenging TMVR space. We can now explore potential co-development applications across the full spectrum of transcatheter valves.”
“For the millions of patients suffering from MR,” said Paterson, “Admedus is proud to provide the transformative healing advantages of ADAPT treated tissue, which has demonstrated clinically superior performance over nine years.” The proven benefits of Admedus’ ADAPT tissue include: native cell integration, a unique calcium resistance, strength and elasticity – and no aldehyde toxicity, no antigenic stimulus, no foreign body reaction, and no immunogenic stimulus. The properties of ADAPT tissue are such that it becomes naturalized in the body with native tissue and is thus a truly regenerative technology. “This is a major milestone for our organization,” said Robert Thatcher, President and CEO of 4C Medical. “The ADAPT tissue, in conjunction with our novel technology for treating patients suffering from mitral regurgitation is a true synergistic effort to bring new solutions for patients around the world who can't undergo surgical valve procedures today.”
Expand
(20min delay)